Meiragtx Holdings (MGTX) Gets a Buy from Evercore ISI
Evercore ISI analyst Gavin Clark-Gartner maintained a Buy rating on Meiragtx Holdings (MGTX – Research Report) on March 14 and set a price ...
MeiraGTx price target raised to $14 from $12 at BofA
BofA analyst Alec Stranahan raised the firm’s price target on MeiraGTx (MGTX) to $14 from $12 and keeps a Buy rating on the shares, citing a ...
This Founder’s Gene Therapy Company Helped Blind Kids See Again
Zandy Forbes’ biotech company MeiraGTx has developed targeted gene therapy methods to treat more than just genetic disorders.
Fierce Biotech3d
Hologen AI commits $430M to MeiraGTx Parkinson’s gene therapy
With MeiraGTx eyeing up how to take the drug through phase 3 and onto commercialization, Hologen has stepped in. The ...
MedCity News3d
Gene Therapy Biotech MeiraGTx Strikes Deal Bringing Generative AI to Pivotal Parkinson’s Trial
MeiraGTx has one gene therapy in a potentially pivotal clinical trial for cancer patients and another gene therapy ready to start Phase 3 in Parkinson’s disease. Completing the studies will be ...
MeiraGTx (MGTX) Expected to Announce Earnings on Thursday
MeiraGTx (NASDAQ:MGTX – Get Free Report) will likely be releasing its earnings data before the market opens on Thursday, ...
MeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business Updates
Today announced strategic collaboration with Hologen AI, including a $200 million upfront payment to MeiraGTx and the formation of a joint venture, Hologen Neuro AI Ltd, with a further $230 million in ...
MeiraGTx Shares Rise on Collaboration with Hologen
MeiraGTx Holdings shares rose 13% in premarket trading on a collaboration with Hologen that will bring in a cash infusion and create a joint venture. Shares were trading around $7.28. The stock is up ...